Domo signs strategic collaboration agreement with AWS for AI solutions
Michael Richard Feldschuh, the Chief Executive Officer of Daxor Corp (NYSE:NASDAQ:DXR), has increased his stake in the company through a recent purchase of shares. According to a recent SEC filing, Feldschuh acquired 647 shares of Daxor common stock on March 19, 2025, at a price of $8.15 per share, totaling approximately $5,273. The purchase comes as the stock has shown strong momentum, with a 7.5% gain year-to-date, though analysts see significant upside potential with price targets ranging from $22 to $25. Following this transaction, Feldschuh holds 209,631 shares directly. This move reflects a continued commitment by the CEO to the company, as he strengthens his position in the New York-based medical instruments firm. According to InvestingPro, while Daxor has been profitable over the last twelve months, analysts anticipate a sales decline in the current year. For deeper insights into insider trading patterns and 8 additional key ProTips for DXR, subscribers can access the comprehensive Pro Research Report.
In other recent news, Daxor Corporation reported a remarkable 116.5% increase in revenue for the fourth quarter of 2024 compared to the previous year. The company also achieved a milestone by reaching cash flow breakeven in the first quarter of 2025. Daxor is in the process of resubmitting its next-generation blood volume analyzer for FDA approval, aiming for a 510(k) clearance. The company anticipates significant market interest in this new system, which is expected to enhance its market positioning.
Additionally, Daxor plans to transition its company designation from the 1940 Act to the 1934 Act, which may provide strategic advantages. The company has also expanded its market presence by acquiring new accounts and increasing kit sales. Furthermore, Daxor has entered into an agreement to acquire intellectual property from a key supplier, which is expected to improve its manufacturing capabilities. These developments highlight Daxor’s ongoing efforts to strengthen its financial performance and market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.